A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. These ...

Due to its critical pathogenic role, JAK2 has become an important therapeutic target. The four currently approved JAK2 ...

A hallmark clinical manifestation of myelofibrosis is splenomegaly, which reflects splenic extramedullary hematopoiesis (EMH) ...

USA: In a groundbreaking development in dermatology, the efficacy, safety, and long-term disease control of Ruxolitinib Cream ...

Scientists have identified four types of JAK: JAK1 JAK2 JAK3 tyrosine kinase 2 (TYK2) These enzymes activate proteins that carry signals from one part of the immune system to another. Blocking the ...

The MHH joint project TARGET-MPN is investigating why the disease persists and progresses in malignant bone marrow diseases from the group of myeloproliferative neoplasms despite targeted treatment.

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

Unlike Ruxolitinib, which inhibits both wild-type and V617F mutation-positive cells, 058 selectively binds to the JAK2 JH2 ...

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant ...

Incyte to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists with the potential to ...